Texas Family Practice Nurse Practitioner Prescribing Prohibitions
Texas family practice nurse practitioners are prohibited from prescribing Schedule II controlled substances (including stimulants like Adderall and methylphenidate) without a collaborative practice agreement with a physician, and they cannot prescribe methadone for opioid use disorder under any circumstances, as methadone can only be dispensed through federally licensed opioid treatment programs. 1
Federal-Level Prescribing Restrictions
Methadone for Opioid Use Disorder
- Methadone for opioid use disorder may be dispensed only through federally licensed opioid treatment programs (OTPs), a restriction that applies to all prescribers regardless of professional designation, including nurse practitioners. 1
- In emergency situations only, any DEA-licensed provider (including NPs with appropriate authority) may administer methadone for up to 72 hours while arranging referral to an OTP. 1
Stimulant Medications - Absolute Contraindications
- Stimulants are contraindicated in patients with a history of illicit use or abuse of stimulants, unless the patient is being treated in a controlled setting or can be supervised closely. 2
- Concomitant use of a monoamine oxidase (MAO) inhibitor is contraindicated with stimulants. 2
- Stimulants should not be administered to a patient with an active psychotic disorder. 2
- Previous sensitivity to stimulant medications, glaucoma, symptomatic cardiovascular disease, hyperthyroidism, and hypertension are contraindications to stimulant use. 2
Opioid Prescribing - Clinical Contraindications
- Opioids are contraindicated when prescribed concurrently with benzodiazepines whenever possible due to increased risk for respiratory depression and overdose. 2
- Clinicians should avoid prescribing opioids to patients receiving opioids from multiple prescribers or those with dangerous combinations of medications identified through prescription drug monitoring programs. 2
Texas-Specific Scope of Practice Limitations
Schedule II Controlled Substances
While the evidence provided does not contain Texas-specific regulations, research demonstrates that restrictive state scope-of-practice laws significantly limit nurse practitioner prescribing authority for controlled substances, with states requiring physician oversight showing substantially lower rates of controlled substance prescribing by NPs (1.1% vs 2.7% in less restrictive states). 3
Buprenorphine Authority
- Nurse practitioners, including family practice NPs, may prescribe buprenorphine for opioid use disorder without federal waivers as of 2022, though the specific scope of practice is governed by state law. 1
- Before 2022 waiver elimination, NPs were limited to treating 30 patients in the first year, expandable to 100 and up to 275 patients with additional qualifications. 1
- NPs can prescribe oral and extended-release injectable naltrexone (Vivitrol) without any special federal waiver. 1
Common Pitfalls and Clinical Caveats
Prescription Drug Monitoring Program (PDMP) Requirements
- Clinicians should check PDMPs in their own and neighboring states (as permitted) before writing prescriptions for medications containing controlled substances. 2
- If patients are found to have high opioid dosages or multiple controlled substance prescriptions from different clinicians, discuss safety concerns and avoid dismissing patients from practice based solely on PDMP information. 2
Documentation Requirements
- Documentation of adequate assessment, previous psychosocial treatments, and previous psychotropic medications is required before prescribing controlled substances. 2
- Urine drug testing should be performed before starting opioid therapy and at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs. 2
Special Population Considerations
- Tricyclic antidepressants are potentially inappropriate for older adults (aged ≥65 years) because of their anticholinergic effects. 2
- Oral NSAIDs should be used with caution, particularly in older persons and in patients with cardiovascular comorbidities, chronic renal failure, or previous gastrointestinal bleeding. 2